<DOC>
	<DOCNO>NCT02966795</DOCNO>
	<brief_summary>A Phase 3b , open-label , multicenter study evaluate efficacy safety glecaprevir ( ABT-493 ) /pibrentasvir ( ABT-530 ) 8- 12-week treatment duration participant chronic Hepatitis C Virus ( HCV ) genotype ( GT ) 5 6 infection , without compensate cirrhosis , either HCV treatment-naïve treatment experience interferon ( IFN ) pegylated interferon ( pegIFN ) without ribavirin ( RBV ) ( define P/R treatment-experienced ) sofosbuvir ( SOF ) plus RBV without pegIFN ( define SOF plus RBV treatment-experienced ) .</brief_summary>
	<brief_title>A Study Glecaprevir/Pibrentasvir Adults With Chronic Hepatitis C Virus ( HCV ) Genotype 5 6 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Screening laboratory result indicate hepatitis C virus ( HCV ) GT5 6 infection . Participant positive antiHCV antibody ( Ab ) plasma HCV ribonucleic acid ( RNA ) great equal 1000 IU/mL Screening Visit . Participant must HCV treatmentnaïve ( i.e. , never receive single dose approve investigational antiHCV medication ) treatmentexperienced ( i.e. , fail prior interferon [ IFN ] pegylated interferon [ pegIFN ] without ribavirin [ RBV ] , sofosbuvir [ SOF ] plus RBV without pegIFN therapy ) . Prior HCV treatment approve investigational medication allow . Previous HCV treatment must complete great equal 2 month prior screen . Participant must document cirrhosis compensate cirrhosis . Female participant pregnant , breastfeeding , consider become pregnant study approximately 30 day last dose study drug . Recent ( within 6 month prior study drug administration ) history drug alcohol abuse could preclude adherence protocol opinion investigator . Positive test result screen hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( HIV Ab ) . HCV genotype perform screen indicate coinfection one HCV genotype . History severe , lifethreatening significant sensitivity excipients study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>sofosbuvir ( SOF )</keyword>
	<keyword>ribavirin ( RBV )</keyword>
	<keyword>pegylated interferon ( pegIFN )</keyword>
	<keyword>interferon ( IFN )</keyword>
	<keyword>pegylated-interferon ( pegIFN )</keyword>
	<keyword>non-cirrhotic</keyword>
	<keyword>glecaprevir</keyword>
	<keyword>compensate cirrhosis</keyword>
	<keyword>pibrentasvir</keyword>
	<keyword>Sustained Virologic Response 12 week post dosing ( SVR12 )</keyword>
</DOC>